Monograph Details
|
|
Respiratory Tract
> Oropharyngeal conditions
|
|
EVOXAC |
| Manufacturer |
|
Daiichi-Sankyo |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Cholinergic (muscarinic) agonist. |
| Generic Name |
|
Cevimeline HCl 30mg; caps. |
| Indications |
|
Dry mouth associated with Sjogren's syndrome. |
| Children |
Not recommended.
|
| Adults |
|
30mg three times daily. |
| Contraindications |
|
Uncontrolled asthma. When miosis is undesirable (eg, acute iritis, narrow-angle glaucoma). |
| Precautions |
|
History of cardiovascular disease. Controlled asthma. Chronic bronchitis. COPD. History of nephrolithiasis or cholelithiasis. CYP2D6 deficiency. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Potentiated by CYP2D6 and CYP3A3/4 inhibitors. Possible conduction disturbances with β-adrenergic antagonists. Additive effects with parasympathomimetics. May interfere with antimuscarinics. |
| Adverse Reactions |
|
Excessive sweating (dehydration may develop; drink extra water), rhinitis, excessive salivation, UTI, cough, arthralgia, fatigue, insomnia, hot flushes, GI upset, visual disturbances (eg, blurring, decreased visual acuity), others. |
| How Supplied |
|
Caps—100 |
|
|
|
|
